Mercure L, Lalonde R, Phaneuf D, Brenner B, Wainberg M A
McGill University AIDS Centre, Montreal, Quebec, Canada.
Clin Diagn Lab Immunol. 1994 Jul;1(4):482-5. doi: 10.1128/cdli.1.4.482-485.1994.
Although several studies have shown that 3'-azido-3'-deoxythymidine (AZT) is not toxic for CD4+ lymphocytes, its effect on CD8+ cells has never been studied in a systematic way. We purified CD8+ cells from the peripheral blood mononuclear cells of both human immunodeficiency virus (HIV)-seronegative and HIV-infected individuals by means of magnetic beads that had been coated with monoclonal antibodies. We report that AZT, but not two other nucleosides tested, inhibited the interleukin-2-dependent proliferation of CD8+ lymphocytes in a dose-dependent manner. No such effect was observed with regard to CD4(+)-enriched populations. The AZT-mediated antiproliferative effect did not appear to be related to either the CD4+ count or to prior treatment with this drug in the case of HIV-seropositive subjects.
尽管多项研究表明3'-叠氮-3'-脱氧胸苷（AZT）对CD4+淋巴细胞无毒，但从未系统研究过其对CD8+细胞的影响。我们通过包被有单克隆抗体的磁珠从人类免疫缺陷病毒（HIV）血清阴性和HIV感染个体的外周血单核细胞中纯化出CD8+细胞。我们报告称，AZT而非另外两种测试的核苷，以剂量依赖方式抑制CD8+淋巴细胞依赖白细胞介素-2的增殖。在富含CD4+的细胞群体中未观察到这种效应。在HIV血清阳性受试者中，AZT介导的抗增殖效应似乎与CD4+细胞计数或此前使用该药物的治疗均无关。
